GHK-Cu: The Copper Tripeptide That Doesn't Behave Like a Cosmetic

GHK-Cu — glycyl-L-histidyl-L-lysine bound to copper — is one of the strangest stories in peptide research. The compound was first isolated from human plasma in 1973 by Loren Pickart, then a Yale doctoral student. The discovery was that aged human liver tissue, exposed to plasma from a young donor, regained some of its regenerative function. The active fraction turned out to be GHK-Cu.

In the half-century since, the compound has accumulated more than 350 peer-reviewed publications. It has been studied in wound healing, hair follicle activation, skin regeneration, anti-fibrotic effects, gene expression modulation, and several cancer-related applications.

This piece walks through what the compound actually does, the human evidence, the practical applications that go beyond skin, and what the longevity research community has been doing with it.

What GHK-Cu does

The mechanism work on GHK-Cu is unusually broad. The compound modulates gene expression — a 2010 paper in BMC Genomics found that GHK-Cu affected the expression of more than 4,000 human genes, predominantly resetting them toward a "younger" expression profile.

The downstream effects observed across the literature:

- **Collagen and elastin synthesis.** Stimulates production of types I and III collagen, elastin, and the structural matrix of skin and connective tissue. - **Wound healing.** Accelerated re-epithelialization, increased blood vessel formation, improved tensile strength of healed tissue. - **Anti-inflammatory.** Reduces expression of inflammatory signaling molecules. - **Antioxidant.** Increases endogenous antioxidant systems, reduces oxidative damage markers. - **Hair follicle.** Stimulates the cells at the base of hair follicles, extends the active growth phase of hair. - **Anti-fibrotic.** Modulates TGF-beta signaling toward repair rather than scar tissue.

The copper component matters. GHK is a tripeptide that binds copper with high affinity, and the copper coordination is essential for many of the biological effects. The copper enzyme lysyl oxidase, critical for collagen and elastin cross-linking, requires GHK-Cu's copper-shuttling function for full activity in tissue.

The human evidence

The clinical data on GHK-Cu in humans is more substantial than for most compounds in the longevity research space:

**Skin regeneration in adults (Dermatologic Surgery, 2009).** Multiple randomized controlled trials demonstrating improved skin density, reduced wrinkle depth, and improved tensile strength on topical use over 12 weeks.

**Wound healing.** A meta-analysis of GHK-Cu in chronic wound healing demonstrated significant improvements in healing rate and final wound quality.

**Diabetic foot ulcer.** GHK-Cu wound treatments have shown efficacy in reducing healing time in diabetic ulcer populations.

**Hair density studies.** Multiple human trials have demonstrated improvements in hair density and follicle diameter on topical GHK-Cu, particularly in androgenetic alopecia populations.

**Photodamage reversal.** Topical GHK-Cu studies in photodamaged skin have shown measurable improvements in skin density and visible signs of UV damage at 12-week endpoints.

The safety profile in the human literature is unusually clean. The compound has been used in topical and subcutaneous applications for decades; documented adverse events are essentially limited to mild skin irritation in topical use and injection-site reactions in subcutaneous use.

What the practical applications look like

The case-report literature and longevity research practice has converged on several application patterns:

**Topical for skin quality.** This is the most common application and where the largest body of human trial data sits. Topical GHK-Cu at research-investigator concentrations (substantially higher than mass-market formulations) produces measurable improvements in skin density, fine lines, and overall skin quality on multi-month protocols.

**Subcutaneous for systemic effects.** Less common in cosmetic-market usage but increasingly common in longevity research applications. Subcutaneous GHK-Cu produces systemic distribution and the gene-expression effects occur in tissues beyond the skin.

**Hair follicle research.** Topical GHK-Cu is one of the better-documented hair density applications, comparable in magnitude to topical minoxidil but through a fundamentally different mechanism.

**Wound and post-procedure recovery.** GHK-Cu shortens healing time and improves final tissue quality after laser, microneedling, or surgical procedures.

The angle most people miss

Here is the thing the cosmetic market does not say:

GHK-Cu's effects on skin are the most-studied and most-marketed application, but they are not the most interesting from a longevity research perspective. The most interesting application is what happens when the gene expression effects are applied systemically.

The 2010 BMC Genomics paper showed that GHK-Cu shifts the expression of thousands of genes toward a younger profile. This is not specific to skin tissue — the transcriptional effects occur across cell types. The implication is that GHK-Cu, used systemically, may produce effects on connective tissue, vascular tissue, and several other systems that the topical-cosmetic application cannot reach.

The Glow Stack

The Glow Stack — the multi-compound research stack focused on appearance and integument outcomes — composes GHK-Cu with complementary compounds: BPC-157 and TB-500 (which address connective-tissue and wound-healing in a parallel mechanism). The mechanistic rationale is that GHK-Cu addresses gene expression and matrix synthesis; BPC-157 and TB-500 address cellular repair and blood vessel formation. Together they cover the relevant pathways more completely than any single compound.

Practical considerations

A few angles worth understanding:

**Topical versus subcutaneous.** Choose based on the application. Skin-quality and hair-density work uses topical preparations. Connective tissue and systemic effects use subcutaneous administration. The two can be used in parallel.

**Concentration matters.** Mass-market cosmetic formulations of GHK-Cu typically contain 0.1% or less. The research-trial formulations often use 1 to 2% topically. The dose-response curve in the literature is steep enough that this difference matters.

**Reconstitution and storage.** GHK-Cu in lyophilized form is stable for extended periods. Reconstituted product is best stored at 36 to 46 degrees Fahrenheit.

GHK-Cu and the Glow Stack are stocked through our laboratory partner network at research-grade purity. Each batch is HPLC and mass spectrometry verified. Certificates of Analysis available on every SKU.